Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Operating Leases (2019 - 2025)

Historic Operating Leases for Agios Pharmaceuticals (AGIO) over the last 7 years, with Q3 2025 value amounting to $44.5 million.

  • Agios Pharmaceuticals' Operating Leases fell 2682.55% to $44.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $44.5 million, marking a year-over-year decrease of 2682.55%. This contributed to the annual value of $40.2 million for FY2024, which is 2944.66% down from last year.
  • Per Agios Pharmaceuticals' latest filing, its Operating Leases stood at $44.5 million for Q3 2025, which was down 2682.55% from $48.8 million recorded in Q2 2025.
  • Agios Pharmaceuticals' 5-year Operating Leases high stood at $103.0 million for Q1 2021, and its period low was $40.2 million during Q4 2024.
  • Over the past 5 years, Agios Pharmaceuticals' median Operating Leases value was $75.5 million (recorded in 2023), while the average stood at $74.1 million.
  • Its Operating Leases has fluctuated over the past 5 years, first tumbled by 673.09% in 2021, then tumbled by 2944.66% in 2024.
  • Quarter analysis of 5 years shows Agios Pharmaceuticals' Operating Leases stood at $85.7 million in 2021, then fell by 15.95% to $72.0 million in 2022, then dropped by 20.85% to $57.0 million in 2023, then fell by 29.45% to $40.2 million in 2024, then grew by 10.71% to $44.5 million in 2025.
  • Its Operating Leases was $44.5 million in Q3 2025, compared to $48.8 million in Q2 2025 and $52.9 million in Q1 2025.